| Patents for A61K 31 - Medicinal preparations containing organic active ingredients (785,912) |
|---|
| 04/24/2014 | WO2014063167A1 Thiazole-based inhibitors of scavenger receptor bi |
| 04/24/2014 | WO2014063107A2 Stable peracid-containing compositions |
| 04/24/2014 | WO2014063105A1 Vitamin d analogues for the treatment of a neurological disorder |
| 04/24/2014 | WO2014063101A1 Formulations of pyrimidinedione derivative compounds |
| 04/24/2014 | WO2014063080A1 Treating polycystic kidney disease with hsp90 inhibitory compounds |
| 04/24/2014 | WO2014063068A1 Inhibitors of cyclin-dependent kinase 7 (cdk7) |
| 04/24/2014 | WO2014063061A1 Hydrophobically tagged small molecules as inducers of protein degradation |
| 04/24/2014 | WO2014063057A1 Compositions and methods for the treatment of parkinson's disease |
| 04/24/2014 | WO2014063054A1 Bone marrow on x chromosome kinase (bmx) inhibitors and uses thereof |
| 04/24/2014 | WO2014063024A1 Preparation of and formulation comprising a mek inhibitor |
| 04/24/2014 | WO2014062960A1 Treatment and prevention of mastitis |
| 04/24/2014 | WO2014062938A1 Rory modulators |
| 04/24/2014 | WO2014062888A1 Compositions and methods for treating stroke |
| 04/24/2014 | WO2014062878A2 Treatment of cancer with tor kinase inhibitors |
| 04/24/2014 | WO2014062838A2 Pkm2 modulators and methods for their use |
| 04/24/2014 | WO2014062801A1 Production of stable non-polyadenylated rnas |
| 04/24/2014 | WO2014062794A1 Compositions and methods for improving glucose uptake |
| 04/24/2014 | WO2014062774A1 Pyrazolopyrimidine compounds for the treatment of cancer |
| 04/24/2014 | WO2014062732A1 Substituted benzene compounds |
| 04/24/2014 | WO2014062720A2 Methods of treating cancer |
| 04/24/2014 | WO2014062667A1 Phenyl linked quinolinyl modulators of ror-gamma-t |
| 04/24/2014 | WO2014062658A1 Methylene linked quinolinyl modulators of ror-gamma-t |
| 04/24/2014 | WO2014062621A1 Treatment of autophagy-based disorders and related pharmaceutical compositions, diagnostic and screening assays and kits |
| 04/24/2014 | WO2014062604A1 Compounds useful as inhibitors of atr kinase |
| 04/24/2014 | WO2014062596A1 2'-methyl substituted nucleoside derivatives and methods of use thereof for the treatment of viral diseases |
| 04/24/2014 | WO2014062553A1 Tricyclic substituted thiadiazine dioxide compounds as bace inhibitors, compositions, and their use |
| 04/24/2014 | WO2014062552A1 Methods for maintaining eye health and ameliorating opthalmic maladies in animals |
| 04/24/2014 | WO2014062549A1 Tricyclic substituted thiadiazine dioxide compounds as bace inhibitors, compositions, and their use |
| 04/24/2014 | WO2014062548A1 Tetrahydroimdidazopyrazine derivatives as cgrp receptor antagonists |
| 04/24/2014 | WO2014062533A1 2-pyridyloxy-3-ester-4-nitrile orexin receptor antagonists |
| 04/24/2014 | WO2014062511A1 Therapeutic compounds and compositions |
| 04/24/2014 | WO2014062494A1 Compositions and methods for the transdermal delivery of methylphenidate |
| 04/24/2014 | WO2014062480A1 Animal feed and/or water amendments for lowering ammonia concentrations in animal excrement |
| 04/24/2014 | WO2014062454A1 Compositions and methods for treating cancer |
| 04/24/2014 | WO2014062347A1 Antibacterial monomers, antibacterial resins and dental composites comprising the antibacterial resins |
| 04/24/2014 | WO2014062228A1 An improved nanovector based drug delivery system for overcoming drug resistance |
| 04/24/2014 | WO2014062204A1 Matrix metalloproteinase inhibitors and methods for the treatment of pain and other diseases |
| 04/24/2014 | WO2014062143A2 Anticholinergic agent combinations |
| 04/24/2014 | WO2014062083A1 Pharmaceutical composition on the basis of phyto-nutrients with increased bioavailability, having anti-tumour activity, and method for producing said composition (alternatives) |
| 04/24/2014 | WO2014062080A1 Medicated wound-healing aid for treating wounds and burns |
| 04/24/2014 | WO2014062044A1 Fluorinated benzenesulfonamides as inhibitors of carbonic anhydrase |
| 04/24/2014 | WO2014061970A1 Sodium channel blockers, preparation method thereof and use thereof |
| 04/24/2014 | WO2014061937A1 Pharmaceutical composition for topical administration comprising piperacillin or its salt, tazobactam or its salt and dexamethasone phosphate or its salt |
| 04/24/2014 | WO2014061828A1 Treatment of scleroderma using an inhibitor of cbp/catenin |
| 04/24/2014 | WO2014061827A1 Treatment of pulmonary fibrosis using an inhibitor of cbp/catenin |
| 04/24/2014 | WO2014061826A1 Treatment of hyperproliferative and pre-cancerous skin diseases using an inhibitor of cbp/catenin |
| 04/24/2014 | WO2014061825A1 Treatment of viral and infectious diseases using an inhibitor of cbp/catenin |
| 04/24/2014 | WO2014061824A1 Methods for treating eye disorders |
| 04/24/2014 | WO2014061823A1 Method for treating type i and type ii diabetes |
| 04/24/2014 | WO2014061821A1 Grb10 interacting gyf protein 2 modulator |
| 04/24/2014 | WO2014061808A1 Nutritional composition for gastrostomy-tube patients |
| 04/24/2014 | WO2014061764A1 Xanthene derivative |
| 04/24/2014 | WO2014061752A1 Compound; tautomer and geometric isomer thereof; salt of said compound, tautomer, or geometric isomer; method for manufacturing said compound, tautomer, isomer, or salt; antimicrobial agent; and anti-infective drug |
| 04/24/2014 | WO2014061714A1 Silicon-containing carboxylic acid derivative |
| 04/24/2014 | WO2014061693A1 Novel non-aromatic carbocyclic or non-aromatic heterocyclic derivative |
| 04/24/2014 | WO2014061676A1 Heterocyclic compound |
| 04/24/2014 | WO2014061647A1 Prenyloxyquinoline carboxylic-acid derivative |
| 04/24/2014 | WO2014061419A1 Novel cancer marker and utilization thereof |
| 04/24/2014 | WO2014061277A1 Antibody-drug conjugate produced by binding through linker having hydrophilic structure |
| 04/24/2014 | WO2014061031A1 2-phenyl-5-heterocyclyl-tetrahydro-2h-pyran-3-amine compounds for use in the treatment of diabetes and its associated disorders |
| 04/24/2014 | WO2014060962A1 Pemetrexed dipotassium formulations |
| 04/24/2014 | WO2014060959A1 Crystalline pemetrexed dipotassium process |
| 04/24/2014 | WO2014060953A1 Process for preparing pemetrexed di potassium and its hydrates |
| 04/24/2014 | WO2014060857A1 Pharmaceutical compositions of diclofenac or salts thereof |
| 04/24/2014 | WO2014060856A1 Pharmaceutical compositions of diclofenac or salts thereof |
| 04/24/2014 | WO2014060855A1 Pharmaceutical compositions of diclofenac or salts thereof |
| 04/24/2014 | WO2014060847A1 Use of long chain polyunsaturated fatty acid derivatives to treat sickle cell disease |
| 04/24/2014 | WO2014060803A1 Prenylated chalcone formulation for the treatment of bees |
| 04/24/2014 | WO2014060770A1 Bicyclic heterocycle compounds and their uses in therapy |
| 04/24/2014 | WO2014060768A1 Bicyclic heterocycle compounds and their uses in therapy |
| 04/24/2014 | WO2014060767A1 Bicyclic heterocycle compounds and their uses in therapy |
| 04/24/2014 | WO2014060763A1 Compounds useful for treating ocular neovasculan |
| 04/24/2014 | WO2014060742A1 Tert-butyl n-[2-{4-[6-amino-5-(2,4-difluorobenzoyl)-2-oxopyridin-1(2h)-yl]-3,5- difluorophenyl}ethyl]-l-alaninate or a salt, hydrate or solvate thereof |
| 04/24/2014 | WO2014060638A1 A veterinary method of alleviating noise aversion |
| 04/24/2014 | WO2014060588A1 2,3-dihydroquinazolin-4(1 h)-one derivatives for use in the treatment of viral infections |
| 04/24/2014 | WO2014060586A1 New compounds having a protective activity against toxins with intracellular activity |
| 04/24/2014 | WO2014060581A1 Use of hydroxytirosol and derivatives thereof as quorum quenchers |
| 04/24/2014 | WO2014060561A1 Oral pharmaceutical formulations comprising dabigatran |
| 04/24/2014 | WO2014060560A1 Solid oral formulations of prasugrel |
| 04/24/2014 | WO2014060554A1 Prasugrel formulations |
| 04/24/2014 | WO2014060548A1 Anthocyanidin complex for the treatment of multiple myeloma |
| 04/24/2014 | WO2014060545A1 Pharmaceutical compositions of dabigatran free base |
| 04/24/2014 | WO2014060512A1 Fatty acid acylated amino acids for growth hormone delivery |
| 04/24/2014 | WO2014060509A1 Use of a bioactivated phytochemical as a neuroprotective agent for preventing and treating disorders related to nervous system |
| 04/24/2014 | WO2014060501A1 Agent for alleviating or treating migraine pain |
| 04/24/2014 | WO2014060493A2 N-(pyridin-2-yl)pyrimidin-4-amine derivatives containing a sulfone group |
| 04/24/2014 | WO2014060464A1 Process for preparing roflumilast |
| 04/24/2014 | WO2014060449A1 Multicomponent crystalline system comprising nilotinib and selected co-crystal formers |
| 04/24/2014 | WO2014060442A1 Vcp inhibitor for use in the prevention of virus infection |
| 04/24/2014 | WO2014060432A1 Pyrrolotriazinone derivatives as pi3k inhibitors |
| 04/24/2014 | WO2014060431A1 Pyrrolotriazinone derivatives as pi3k inhibitors |
| 04/24/2014 | WO2014060411A1 Rsv antiviral compounds |
| 04/24/2014 | WO2014060408A1 Anthracyline derivatives for treating tumor diseases |
| 04/24/2014 | WO2014060398A1 Ethynyl derivatives as modulators of mglur5 receptor activity |
| 04/24/2014 | WO2014060395A1 Serine/threonine kinase inhibitors |
| 04/24/2014 | WO2014060394A1 Ethynyl derivatives as modulators of mglur5 receptor activity |
| 04/24/2014 | WO2014060392A1 Caspase-6 inhibitors for treating t cell activation and/or proliferation disorders |
| 04/24/2014 | WO2014060386A1 Indol-amide compounds as beta-amyloid inhbitors |
| 04/24/2014 | WO2014060384A1 Ethynyl derivatives as modulators of mglur5 receptor activity |
| 04/24/2014 | WO2014060376A1 4-(ortho)-fluorophenyl-5-fluoropyrimidin-2-yl amines containing a sulfone group |